Article
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Pharmacogenetics and genomics - 1 Jul 2007
Jaremko Malgorzata, Justenhoven Christina, Schroth Werner, Abraham Benny K, Fritz Peter, Vollmert Caren, Illig Thomas, Simon Wolfgang, Schwab Matthias, Brauch Hiltrud
Abstract excerpt
OBJECTIVES: Outcome and survival in anthracycline-based and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of invasive breast cancer are unpredictable. Insights into treatment prediction are expected from studies searching for an association between genetic polymorphisms and treatment outcome effects. A common feature of treatment with chemoreagents is therapeutically induced DNA damage....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.